:: Main :: About :: Current Issue :: Archive :: Submit :: Contact ::
:: Volume 6, Issue 1 (6-2019) ::
vacres 2019, 6(1): 29-32 Back to browse issues page
The Current Status of Bacillus Calmette‐Guérin Vaccine Protective Efficacy
Patricia Méndez-Samperio *
Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional
Abstract:   (3072 Views)
The bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) remains with poor protective efficacy. However BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status, and main challenges for the development of a safer and more efficient TB vaccine.
Keywords: |BCG|global health|clinical trials|tuberculosis|vaccine ,
Full-Text [PDF 374 kb]   (401 Downloads)    
Type of Study: Review article | Subject: Vaccine development, efficacy and safety evaluation
Received: 2020/01/16 | Accepted: 2020/03/11 | Published: 2020/04/13
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Méndez-Samperio P. The Current Status of Bacillus Calmette‐Guérin Vaccine Protective Efficacy. vacres. 2019; 6 (1) :29-32
URL: http://vacres.pasteur.ac.ir/article-1-166-en.html

Volume 6, Issue 1 (6-2019) Back to browse issues page
Vaccine Research Vaccine Research
Persian site map - English site map - Created in 0.17 seconds with 31 queries by YEKTAWEB 4296
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.